Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.

[1]  J. Radich,et al.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. , 2011, Cancer cell.

[2]  A. Bennaceur-Griscelli,et al.  Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. , 2011, Blood.

[3]  H. Kantarjian,et al.  Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[5]  B. Druker,et al.  Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.

[6]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[7]  C. Lassen,et al.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein , 2010, Proceedings of the National Academy of Sciences.

[8]  T. Skorski,et al.  Chronic myeloid leukemia: mechanisms of blastic transformation. , 2010, The Journal of clinical investigation.

[9]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[10]  Manuel Ayala,et al.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. , 2010, The New England journal of medicine.

[11]  D. Tenen,et al.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. , 2010, Blood.

[12]  R. Hoffman,et al.  The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. , 2010, Cancer research.

[13]  F. Gasparri,et al.  Cell Proliferation Method: Click Chemistry Based on BrdU Coupling for Multiplex Antibody Staining , 2008, Current protocols in cytometry.

[14]  M. Clarke,et al.  Long-term haematopoietic reconstitution by Trp53-/-p16Ink4a-/-p19Arf-/- multipotent progenitors , 2008, Nature.

[15]  E. Schwarz,et al.  TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood , 2008, Arthritis research & therapy.

[16]  M. Konopleva,et al.  CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells , 2008, Molecular Cancer Therapeutics.

[17]  Shamit Soneji,et al.  Molecular evidence for hierarchical transcriptional lineage priming in fetal and adult stem cells and multipotent progenitors. , 2007, Immunity.

[18]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[19]  H. Gendelman,et al.  HIV‐1‐infected and/or immune activated macrophages regulate astrocyte SDF‐1 production through IL‐1β , 2006, Glia.

[20]  R. A. Etten,et al.  Requirement for CD44 in homing and engraftment of BCR-ABL–expressing leukemic stem cells , 2006, Nature Medicine.

[21]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[22]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[23]  D. Campana,et al.  Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase , 2003, British journal of haematology.

[24]  M. Slovak,et al.  Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. , 2002, Blood.

[25]  R. Alon,et al.  Immature Leukemic CD34+CXCR4+ Cells from CML Patients Have Lower Integrin‐Dependent Migration and Adhesion in Response to the Chemokine SDF‐1 , 2002, Stem cells.

[26]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[27]  George Q. Daley,et al.  The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity , 1999, The Journal of experimental medicine.

[28]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[29]  R. Alon,et al.  Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. , 1999, Science.

[30]  Jon C. Aster,et al.  Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .

[31]  A. Sarris,et al.  MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. , 1998, Blood.

[32]  I. Weissman,et al.  Identification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow , 1997, Cell.

[33]  P. Lansdorp,et al.  Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. , 1996, Blood.

[34]  C. Jordan,et al.  High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. , 1996, Experimental hematology.

[35]  C. Verfaillie,et al.  Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. , 1995, Blood.

[36]  C. Eaves,et al.  Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Verfaillie,et al.  Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. , 1992, The Journal of clinical investigation.

[38]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[39]  T. Papayannopoulou,et al.  Hierarchy of molecular-pathway usage in bone marrow homing and its shift by cytokines. , 2006, Blood.

[40]  B. Göttgens,et al.  Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. , 2005, Blood.

[41]  M. Kiel,et al.  Supplemental Data SLAM Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal Endothelial Niches for Stem Cells , 2005 .

[42]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[43]  T. Stankovic,et al.  Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD / SCID mice , 2002 .